Initial treatment of men and women.
| Variables | Men, n = 1142 | Women, n = 4393 | ||
|---|---|---|---|---|
| n (%) | DAS*, mean (SD) | n (%) | DAS*, mean (SD) | |
| csDMARD monotherapy | 421 (36.9) | 3.4 (1.1) | 1804 (41.2) | 3.6 (1.0) |
| MTX | 248 (58.9) | 3.6 (1.2) | 983 (54.5) | 3.8 (1.0) |
| SSZ | 83 (19.7) | 3.2 (1.1) | 181 (10.0) | 3.3 (0.9) |
| HCQ | 80 (19.0) | 2.8 (0.8) | 597 (33.1) | 3.4 (0.9) |
| Other | 10 (2.4) | – | 43 (2.4) | – |
| GC monotherapy | 103 (9.0) | 3.3 (0.9) | 252 (5.7) | 3.3 (0.9) |
| csDMARD combination therapy | 233 (20.4) | 3.5 (1.1) | 947 (21.6) | 3.9 (1.0) |
| MTX + HCQ | 95 (40.8) | 3.3 (1.0) | 554 (57.9) | 3.9 (1.0) |
| MTX + SSZ | 70 (30.0) | 3.6 (1.0) | 192 (20.1) | 3.7 (1.0) |
| MTX + SSZ + HCQ | 40 (17.2) | 3.1 (0.7) | 122 (12.8) | 3.5 (0.9) |
| SSZ + HCQ | 19 (8.2) | 3.3 (0.9) | 48 (5.0) | 3.5 (0.9) |
| MTX + LEF | 5 (2.2) | 4.8 (0.7) | 24 (2.5) | 3.8 (1.2) |
| Other | 4 (1.7) | – | 7 (0.7) | – |
| csDMARD + GC | 271 (23.7) | 3.7 (1.2) | 928 (21.2) | 3.6 (1.0) |
| MTX + GC | 226 (83.4) | 3.7 (1.1) | 705 (76.0) | 3.6 (1.0) |
| HCQ + GC | 21 (7.8) | 3.8 (1.7) | 136 (14.8) | 3.6 (0.9) |
| SSZ + GC | 17 (6.3) | 3.6 (1.3) | 53 (5.7) | 3.8 (1.0) |
| LEF + GC | 4 (1.5) | 3.8 (1.2) | 26 (2.8) | 3.4 (1.1) |
| Other | 3 (1.1) | – | 8 (0.9) | – |
| Combination csDMARD + GC | 114 (10.0) | 3.6 (1.1) | 452 (10.3) | 3.9 (1.0) |
| MTX + HCQ + GC | 48 (42.1) | 3.5 (1.2) | 205 (45.4) | 3.8 (1.0) |
| MTX + SSZ + GC | 26 (22.8) | 3.6 (0.9) | 111 (24.6) | 3.9 (1.0) |
| MTX + SSZ + HCQ + GC | 20 (17.5) | 3.4 (0.8) | 74 (16.4) | 3.6 (1.0) |
| SSZ + HCQ + GC | 13 (11.4) | 3.4 (0.9) | 32 (7.1) | 3.6 (1.0) |
| MTX + LEF + GC | 4 (3.5) | 3.1 (1.2) | 9 (2.0) | 4.3 (1.1) |
| Other | 3 (2.6) | – | 21 (4.6) | – |
↵* DAS based on the non-imputed database. csDMARD: conventional synthetic disease-modifying antirheumatic drugs; MTX: methotrexate; SSZ: sulfasalazine; HCQ: hydroxychloroquine; LEF: leflunomide; GC: glucocorticoid; DAS: Disease Activity Score.